Topotecan

Generic Name: Topotecan

Brand Names: Hycamtin, Potactasol, Topotecan Hospira

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₃N_₃O_₅

CAS Number: 123948-87-8

Unique Ingredient Identifier: 7M7YKX2N15

Background: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.

Indication: 用于小细胞肺癌（SCLC）和一线治疗失败的晚期转移性卵巢癌。

Associated Conditions: Acute Myeloid Leukemia, Ewing's Sarcoma, Refractory Neuroblastoma, Metastatic Rhabdomyosarcoma, Recurrent Stage IVB Cervical Cancer, Refractory CNS lymphoma, Refractory CNS malignancy, Refractory, metastatic Ovarian cancer, Relapsed Platinum Sensitive Small Cell Lung Cancer (SCLC)

Clinical Trials

The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative Vitreoretinopathy

Phase 1

Not yet recruiting

Conditions: Rhegmatogenous Retinal Detachment
Proliferative Vitreoretinopathy
Proliferative Vitreo-Retinopathy

Interventions: Drug: Topotecan

First Posted Date: 2024-05-22

Last Posted Date: 2024-11-25

Lead Sponsor: Massachusetts Eye and Ear Infirmary

Target Recruit Count: 50

Registration Number: NCT06425419

SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

Phase 3

Recruiting

Conditions: Ovarian Cancer

Interventions: Drug: SHR-A1921
Drug: Doxorubicin
Drug: Paclitaxel
Drug: Topotecan

First Posted Date: 2024-05-01

Last Posted Date: 2024-08-09

Lead Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Target Recruit Count: 440

Registration Number: NCT06394492

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
🇨🇳
National Cancer Center/Tumor Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

Phase 3

Recruiting

Conditions: Small Cell Lung Cancer

Interventions: Drug: Ifinatamab deruxtecan
Drug: Topotecan
Drug: Amrubicin
Drug: Lurbinectedin

First Posted Date: 2024-01-12

Last Posted Date: 2025-05-14

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 540

Registration Number: NCT06203210

Locations: 🇺🇸
Highlands Oncology Group, Springdale, Arkansas, United States
🇺🇸
Clinical Research Providence Medical Foundation, Fullerton, California, United States
🇺🇸
UCLA Hematology-Oncology, Los Angeles, California, United States

and more 227 locations

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

Phase 3

Recruiting

Conditions: Ganglioneuroblastoma, Nodular
Neuroblastoma

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Drug: Carboplatin
Drug: Cisplatin
Procedure: Computed Tomography
Drug: Cyclophosphamide
Biological: Dinutuximab
Drug: Doxorubicin
Procedure: Echocardiography Test
Drug: Etoposide
Procedure: FDG-Positron Emission Tomography and Computed Tomography Scan
Procedure: Hematopoietic Cell Transplantation
Drug: Irinotecan
Drug: Isotretinoin
Procedure: Leukapheresis
Procedure: Magnetic Resonance Imaging
Drug: Melphalan
Procedure: Multigated Acquisition Scan
Radiation: Radiation Therapy
Procedure: Radionuclide Imaging
Other: Survey Administration
Drug: Temozolomide
Drug: Thiotepa
Drug: Topotecan
Procedure: Tumor Resection
Drug: Vincristine

First Posted Date: 2023-12-15

Last Posted Date: 2025-05-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 478

Registration Number: NCT06172296

Locations: 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
USA Health Strada Patient Care Center, Mobile, Alabama, United States
🇺🇸
Banner Children's at Desert, Mesa, Arizona, United States

and more 150 locations

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2

Active, not recruiting

Conditions: Solid Cancer

Interventions: Drug: R-DXd
Drug: Gemcitabine
Drug: Paclitaxel
Drug: Topotecan
Drug: PLD

First Posted Date: 2023-12-07

Last Posted Date: 2025-03-27

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 650

Registration Number: NCT06161025

Locations: 🇨🇿
Fakultni nemocnice v Motole, Praha 5, Czechia
🇨🇿
Fakultni nemocnice Bulovka, Praha, Czechia
🇫🇷
Centre Francois Baclesse, Caen Cedex 05, France

and more 79 locations

Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer

Phase 3

Recruiting

Conditions: Relapsed Small Cell Lung Cancer

Interventions: Drug: Irinotecan hydrochloride liposome Injection
Drug: Topotecan

First Posted Date: 2023-11-13

Last Posted Date: 2024-03-15

Lead Sponsor: Luye Pharma Group Ltd.

Target Recruit Count: 686

Registration Number: NCT06128837

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China

DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With Topotecan

Phase 1

Recruiting

Conditions: Small Cell Lung Carcinoma (SCLC)

Interventions: Drug: BI 764532
Drug: Topotecan
Drug: Single agent chemotherapy

First Posted Date: 2023-08-14

Last Posted Date: 2025-04-30

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 90

Registration Number: NCT05990738

Locations: 🇺🇸
Mayo Clinic - Florida, Jacksonville, Florida, United States
🇺🇸
University of Miami, Miami, Florida, United States
🇫🇷
INS Curie, Paris, France

and more 9 locations

Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan

Phase 4

Recruiting

Conditions: Extensive-stage Small-cell Lung Cancer

Interventions: Drug: Placebo
Drug: Trilaciclib
Drug: Topotecan

First Posted Date: 2023-05-24

Last Posted Date: 2023-11-07

Lead Sponsor: G1 Therapeutics, Inc.

Target Recruit Count: 302

Registration Number: NCT05874401

Locations: 🇧🇪
CHU de Liège, Liege, Belgium
🇧🇪
Centre Hospitalier de l'Ardenne, Libramont, Belgium
🇵🇱
Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy, Otwock, Poland

and more 53 locations

REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

Phase 2

Recruiting

Conditions: Ovarian Cancer
Epithelial Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer
Platinum-resistant Ovarian Cancer

Interventions: Drug: Gemcitabine
Drug: Luveltamab tazevibulin
Drug: Pegfilgrastim
Drug: Paclitaxel
Drug: Pegylated liposomal doxorubicin
Drug: Topotecan

First Posted Date: 2023-05-23

Last Posted Date: 2024-08-29

Lead Sponsor: Sutro Biopharma, Inc.

Target Recruit Count: 600

Registration Number: NCT05870748

Locations: 🇺🇸
Texas Oncology, Dallas, Texas, United States
🇺🇸
Ohio State University Center, Columbus, Ohio, United States
🇺🇸
Baptist Health South Florida (BHSF) - Miami Cancer Institute, Miami, Florida, United States

and more 36 locations

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

Phase 2

Recruiting

Conditions: Lung Cancer
Small-cell Lung Cancer
Non Small Cell Lung Cancer

Interventions: Drug: Carboplatin
Drug: Pemetrexed
Drug: Paclitaxel
Drug: Nab paclitaxel
Drug: Docetaxel
Drug: Gemcitabine
Drug: Etoposide
Drug: Irinotecan
Drug: Topotecan
Drug: Lurbinectedin

First Posted Date: 2023-04-05

Last Posted Date: 2025-04-04

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 280

Registration Number: NCT05800587

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy